Study to Evaluate the Safety and Reactogenicity of the HIV Vaccine 732461 in HIV Infected Subjects Aged 18 to 55 Years Old.

Trial Profile

Study to Evaluate the Safety and Reactogenicity of the HIV Vaccine 732461 in HIV Infected Subjects Aged 18 to 55 Years Old.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs GSK 732461 (Primary) ; AS01B
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Oct 2013 Results published in Vaccine.
    • 07 Feb 2012 New profile created for NCT01092611 (213081). This appears to be a follow-up of more than one study. NCT00814762 was conducted only in Germany and enrolled 41 patients while the extension is enrolling 215.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top